Last --
Change Today 0.00 / 0.00%
Volume 0.0
STDAY On Other Exchanges
All times are local (Market data is delayed by at least 15 minutes).

stada arzneimittel-unspn adr (STDAY) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

stada arzneimittel-unspn adr (STDAY) Related Businessweek News

No Related Businessweek News Found

stada arzneimittel-unspn adr (STDAY) Details

STADA Arzneimittel Aktiengesellschaft engages in the development and marketing of active pharmaceutical ingredients for the health care and pharmaceutical markets worldwide. The company operates primarily in two segments, Generics and Branded Products. The Generics segment provides various active ingredients, including stomach medicines, antihypertensive agents, and anti-inflammatory agents. This segment’s primarily products include Phospholipide, a liver medicine; Diclofenac, an antirheumatic drug; Tilidine, an opioid; Enalapril, an ACE inhibitor; and Omeprazole, a stomach medicine. The Branded Products segment offers non-prescription products, such as Grippostad and Ladival. This segment’s products also comprise Apo-Go, a Parkinson medicine; Snup, a nasal preparation; Zaldiar, a pain medicine; Chondroxid for the treatment of degenerative joint diseases; and Ladival, a sun cream. The company has license and collaboration agreements with Gedeon Richter Plc for the development and marketing of biosimilar products for two monoclonal antibodies rituximab and optionally trastuzumab. It serves patients and/or consumers, doctors, doctors’ cooperatives, pharmacies, pharmacy co-operatives, hospitals, wholesalers, and other service providers in the health care market, as well as public health insurance organizations or private insurances. STADA Arzneimittel Aktiengesellschaft was founded in 1895 and is headquartered in Bad Vilbel, Germany.

10,113 Employees
Last Reported Date: 08/7/14
Founded in 1895

stada arzneimittel-unspn adr (STDAY) Top Compensated Officers

Chairman of the Executive Board and Chief Exe...
Total Annual Compensation: €3.2M
Chief Financial Officer and Member of Executi...
Total Annual Compensation: €1.4M
Chief Business Development & Central Services...
Total Annual Compensation: €844.6K
Compensation as of Fiscal Year 2013.

stada arzneimittel-unspn adr (STDAY) Key Developments

Stada-Arzneimittel AG Reports Group Earnings Results for the Six Months Ended June 2014; Re-Affirms Earnings Guidance for the Year 2014

Stada-Arzneimittel AG reported group earnings results for the six months ended June 2014. For the period, the group reported sales of €1,002.8 million compared to €966.8 million, operating profit of €121.2 million compared to €129.5 million, operating profit, adjusted of €152.2 million compared to €135.4 million, EBITDA, reported of €192.1 million compared to €183.4 million, EBITDA, adjusted of €208.3 million compared to €189.1 million, net income, reported of €66.8 million or €1.11 per share compared to €66.6 million or €1.12 per share, net income, adjusted of €90.1 million or €1.49 per share compared to €70.1 million or €1.18 per share for the last year. The executive board confirms the outlook for financial year 2014. According to this, STADA expects slight growth in group sales, adjusted EBITDA and adjusted net income. For the overall year, the company had a tax rate guidance of 26% to 28%. And on an adjusted basis, and at the moment, after the first six months, the company would assume that the tax rate on an adjusted basis will rather be at the lower end of these 26% to 28%, so roughly up to 25% to 26% on an adjusted basis.

STADA AG Presents at 2014 Russian Pharmaceutical Forum, Jun-17-2014 02:55 PM

STADA AG Presents at 2014 Russian Pharmaceutical Forum, Jun-17-2014 02:55 PM. Venue: Corinthia Saint-Petersburu Hotel, 57 Nevskij Prospect, St. Petersburg, Russia. Speakers: Dmitriy Efimov, Senior Vice President for Russia, CIS and South East Europe.

Stada-Arzneimittel AG Approves Dividend for 2013

Stada-Arzneimittel AG announced that at the AGM held on June 4, 2014, the shareholders approved dividend of EUR 0.66 per common share, which is significantly higher than the previous year by 32%, with the remaining surplus being carried forward.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
STDAY:US $0.00 USD 0.00

STDAY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BTG PLC 661.00 GBp +8.50
Richter Gedeon Nyrt 3,894 -21.00
Impax Laboratories Inc $24.58 USD -0.33
Skyepharma PLC 315.00 GBp +20.50
Vernalis PLC 42.75 GBp +0.25
View Industry Companies

Industry Analysis


Industry Average

Valuation STDAY Industry Range
Price/Earnings 14.6x
Price/Sales 0.9x
Price/Book 1.8x
Price/Cash Flow 14.5x
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact STADA ARZNEIMITTEL-UNSPN ADR, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at